PRELID1P7

Across TCGA pan-cancer cohorts, PRELID1P7 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of PRELID1P7’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where PRELID1P7 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRELID1P7 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

THCA, KIRC, and KICH are the cancer types where PRELID1P7 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRELID1P7 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	All	+0.865	<.001	9	view →
KIRC	All	III,IV	−0.013	.010	5	view →
KICH	All	All	+0.134	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

PRELID1P7–THCA

Open the THCA breakdown →